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INTRODUCTION
Oral mucositis (OM) is a common 
complication of chemotherapy and (or) 
radiotherapy, representing respectively, 40% and 
100 % of cases of oral mucosa inflammation1,2. 
Erythema, ulceration, bleeding, swelling and pain 
are among the symptoms and signs, compromising 
nutrition, speech and fluid intake of the patients, 
predisposing them to systemic infection3-5. The 
World Health Organization (WHO) classifies oral 
mucositis into: grade 0: absent; Grade 1: erythema, 
grade 2: erythematous and ulcerated, tolerating 
solids; Grade 3 : erythematous and ulcerated, 
tolerating liquids only; Grade 4: erythematous and 
ulcerated, precluding feeding3. The low power 
laser therapy (LPL) works in the prevention and 
treatment of OM, providing for analgesic and 
anti-inflammatory effects, greater patient comfort, 
maintaining mucosal integrity and better tissue 
repair2-6. With this paper we aim at analyzing the 
effectiveness of laser therapy in the treatment of 
oral mucositis.
CASE PRESENTATION
BMCR - department of pediatric oncology, 
a 15-year-old female diagnosed initially with 
Ewing’s sarcoma in the right clavicle, submitted 
to chemotherapy with ifosfamide, etoposide 
and vincristine (doxorubicin in subsequent 
cycles) under parenteral nutrition, complaining 
of intense pain. She had febrile neutropenia 
and pancytopenia, the patient received packed 
red blood cells and platelets and granulokine, 
cefepime, fluconazole and nystatin. Undergoing 
orthodontic treatment, with poor oral hygiene, 
she developed grade 3 mucositis lesions (WHO) 
in the buccal mucosa and left retromalar triangle. 
The dentist removed the device, removed the 
biofilm and polished her teeth. Laser therapy 
was instated three times a week for treatment 
of the mucositis lesions. We started with the 
780 nm wavelength (λ) and an energy density 
of 4.3 J/cm2, and analgesic agent around the 
lesions. In the second session, we employed the 
therapeutic LPL at λ 660 nm, at an energy density 
of 4.3 J/cm2, around the lesions (Figure 1). BMCR 
was instructed concerning oral hygiene and use 
of mouthwashes with chlorhexidine gluconate 
at 0.12%. After the first session, pain subsided 
and after the second, the patient was fed; after 
the fourth session, the lesions had decreased, 
healing almost entirely after the fifth application. 
A new cycle of chemotherapy was started two 
weeks later. Preventive laser at λ 660 nm, energy 
density of 1.3 J/cm2 per point in the region of the 
buccal mucosa, mouth floor, tongue and palate, 
three times a week, was applied in order to avoid 
lesion recurrence. Currently, in the fourth cycle of 
chemotherapy, the patient no longer developed 
mucositis lesions. Thus proving the functional and 
clinical efficacy of the LPL: accelerating wound 
healing, reducing pain and length of hospital stay.
DISCUSSION
Oral mucositis is defined as an inflam-
mation and ulceration of the oral mucosa with 
pseudomembrane formation and potential source 
of infection, particularly febrile neutropenia1, 
such as it happened with our patient (BMCR). 
Pathologically, in mucositis there is a shallow 
ulcer generating interstitial exudate, cellular 
debris and fibrin, producing a pseudomembrane 
analogous to a superficial skin scar. The 
chemotherapy-induced mucositis varies from 
40 % to 76 % for patients treated with standard 
and high-dose chemotherapy, respectively1. 
In intensive chemotherapy for relapse after 
remission, the association with ifosfamide, 
carboplatin and etoposide, and irinotecan 
are known to be toxic for the oral mucosal2. 
Antimetabolite agents (methotrexate, cytarabine, 
mercaptopurine), alkylating agents (melphalan 
busulphan), antibiotics (Doxorubicin) and 
etoposide, both used by the patient, also induce 
mucositis1,2,6. In this case, the LPL eliminates 
pain already at the first application. This fact is 
attributed to the release of ß-endorphin in the 
nerve endings of the ulcer, while promoting tissue 
biostimulation, quickly repairing the ulcerations2.
FINAL COMMENTS
It is necessary to encourage the use of 
low-power laser for the prevention and treatment 
of oral mucositis in cancer patients. It is a low 
cost and viable option in otorhinolaryngology, 
without side effects.
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Figure 1. Region submitted to the laser therapy (660 nm 
wavelength, energy density of 4.3 J/cm²) - buccal mucosa.
